(2003; 67 pages)
Significant problems of substandard products exist within the drug distribution chains. Percentage failure of samples based on ingredient content ranging from 20% to 67% for CQT and 5% to 28% for SPT, and in dissolution failures ranging from 5% to 33% for CQT and 75% to 100% for SPT, cannot be ignored. In view of the potential danger that substandard antimalarials could already be posing in the fight against malaria, an intervention plan should be developed immediately. This could involve setting up quality surveillance systems within drug regulatory authorities in the region and supporting manufacturers to improve GMP compliance.